p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Hanna Berglund(Uppsala University), Marika Nestor(Uppsala University)
European Journal of Nuclear Medicine and Molecular Imaging
October 12, 2023
Cited by 6
Related Papers
Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells
|PLoS ONE|2014|207
The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells
|International Journal of Oncology|2019|30
Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2
|EJNMMI Research|2020|7
The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model
|Frontiers in Oncology|2020|6
Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts
|Molecular Cancer Therapeutics|2025|6